Murakami Naoka, Motwani Shveta, Riella Leonardo V
Schuster Family Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Boston, Massachusetts; Renal Division, Brigham and Women's Hospital, Boston, Massachusetts.
Renal Division, Brigham and Women's Hospital, Boston, Massachusetts; Adult Survivorship Program, Dana Farber Cancer Institute, Boston, Massachusetts.
Curr Probl Cancer. 2017 Mar-Apr;41(2):100-110. doi: 10.1016/j.currproblcancer.2016.12.004. Epub 2016 Dec 19.
Immune checkpoint inhibitors have been approved for a variety of cancer species. Renal complications in use of these agents are not very common compared with other immune-related adverse events (irAE). However, it is crucial for physicians to recognize and manage renal manifestations of irAE. In this review, we will summarize the up-to-date knowledge of the clinical presentation, pathologic features, and management of renal irAE. In addition, we will discuss the safety of immune checkpoint inhibitors in patients with chronic kidney disease as well as in kidney transplant recipients.
免疫检查点抑制剂已被批准用于多种癌症。与其他免疫相关不良事件（irAE）相比，使用这些药物时出现的肾脏并发症并不常见。然而，医生认识并处理irAE的肾脏表现至关重要。在本综述中，我们将总结irAE的临床表现、病理特征及处理方面的最新知识。此外，我们还将讨论免疫检查点抑制剂在慢性肾脏病患者以及肾移植受者中的安全性。
